A case of refractory pediatric Crohn's disease with a successful treatment by infliximab therapy
- Park S.H.; Jeen Y.T.; Chun H.R.; Kim D.I.; Baeck C.W.; Kim Y.S.; Chun H.J.; Lee H.S.; Um S.H.; Choi J.H.; Kim C.D.; Ryu H.S.; Hyun J.H.
- Issue Date
- Crohn' s disease; Pediatrics; Infliximab
- The Korean journal of gastroenterology, v.46, no.4, pp.297 - 301
- Journal Title
- The Korean journal of gastroenterology
- Start Page
- End Page
- Crohn's disease is a chronic inflammatory bowel disease which affects mainly children and young adults, and its cause remains unknown so far. Infliximab, a monoclonal antibody to the pivotal cytokine tumor necrosis factor-alpha, has been approved as a drug for both induction and maintenance therapy for moderately to severely active, or fistula-complicated Crohn's disease. The authors report a 12-year-old male patient diagnosed as Crohn's disease complicated with a perianal fistula, which was refractory to the conventional therapy. After the 0, 2, and 6 week scheduled intravenous infusion of infliximab, the patient reached to clinical remission in both subjective symptoms and objective manifestations. For children or young adults who develop Crohn's disease in a refractory course, infliximab may serve as a drug which leads to a clinical improvement or even to an extent of remission.
- Files in This Item
- There are no files associated with this item.
- Appears in
- 2. Clinical Science > Department of Internal Medicine > 1. Journal Articles
- 5. Others > Others(Medicine) > 1. Journal Articles
- 2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.